These Analysts Boost Their Forecasts On Vir Biotechnology

Vir Biotechnology reported a fourth-quarter loss of 31 cents, beating the consensus loss of 41 cents. Sales reached $64.07 million, surpassing the consensus of $23.18 million.The partnership with the Japanese drugmaker announced on Monday aims to advance VIR-5500, an investigational treatment for prostate cancer, which is expected to enhance the company's oncology pipeline as it seeks to address a critical area in cancer treatment to advance PSMA targeting.On Monday, Vir Biotechnology shared new data from t ...